Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds ...
TRENTON, N.J. (AP) — Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or ...
An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary ...
Patients who used aspirin, NSAIDs or anti-clotting drugs prior to a GI procedure did not have an increased bleeding risk, according to research presented at the American College of Gastroenterology’s ...
ORLANDO, Fla. – Adding Plavix to other anti-clotting drugs typically given to heart attack patients saves lives and prevents second heart attacks, two huge international studies found. The strategy is ...
Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds ...
Opeolu Adeoye, MD, and Peter Panagos, MD, (right) both professors of emergency medicine at Washington University School of Medicine in St. Louis, analyze a brain scan for stroke damage. Adeoye led a ...
A million Americans who have had heart attacks or strokes caused by blood clots now take anti-clotting drugs regularly to cut down the danger of recurrences. But their blood takes so much longer to ...
(Reuters) - U.S. regulators on Thursday approved the use of a drug made by Daiichi Sankyo Co Ltd to reduce the risk of stroke and blood clots in patients with an irregular heartbeat not caused by a ...
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
NEW YORK, Oct 22 (Reuters) - Schering-Plough Corp on Monday said its experimental anti-clotting drug, as in an earlier trial, met its main goal in two additional mid-stage trials of not increasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results